Scynexis Inc (SCYX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $31.95M
Last updated: Nov 17, 2026 at 4:10 PM ET
Scynexis Inc (SCYX) Statistics
Scynexis (SCYX) has a market cap of $31.95M and an enterprise value of $24.27M. Revenue grew 543.96% over the last 12 months from the 12 months before. It kept -53.50% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 24.03% below the market cap, as cash exceeds debt.
| Market Cap | $31.95M |
|---|---|
| Enterprise Value | $24.27M |
| Latest price (Nov 17, 2026) | $2.85 |
Key Dates
The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.8x and 0.6x. Its year-end P/S ranged from 0.8x to 384.4x from 2016 to 2025.
| P/S Ratio | 1.8x |
|---|---|
| Forward P/S | 81.2x |
| P/B Ratio | 0.6x |
Price Statistics
The stock is down 39.19% over 52 weeks and trades 30.66% below its 50-day average.
| Beta (1Y) | 1.63 |
|---|---|
| 52-Week Change | -39.19% |
| 1-Month Change | -22.13% |
| 3-Month Change | -44.66% |
| 6-Month Change | -45.76% |
| 5-Year Change | -90.59% |
| 10-Year Change | -98.53% |
| Total Return (1Y) | -39.19% |
| Total Return (3Y CAGR) | -39.63% |
| Total Return (5Y CAGR) | -43.51% |
| Return vs SPY (1Y) | -50.12% |
| Max Drawdown (1Y) | -67.91% |
| Max Drawdown (3Y) | -87.14% |
| Sharpe Ratio (1Y) | -0.66 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $4.11 |
| 200-Day Average | $5.40 |
| 52-Week Range | $2.84 to $9.12 |
| RSI (14 Days) | 25.5 |
| Average Volume (20 Days) | 67.55K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.57x current liabilities, and total debt is 0.01x shareholder equity.
| Current Ratio | 7.57x |
|---|---|
| Quick Ratio | 7.57x |
| Debt / Equity | 0.01x |
| Interest Coverage | 11.32x |
Returns and Efficiency
Return on invested capital is -16.41% over the last 12 months, against a 5-year average of -28.16%.
| Return on Equity (ROE) | -17.11% |
|---|---|
| Return on Assets (ROA) | -14.87% |
| Return on Invested Capital (ROIC) | -16.41% |
| ROA (5Y Average) | -16.96% |
| ROIC (5Y Average) | -28.16% |
| Asset Turnover | 0.32x |
Scores
SCYX has an Altman Z-Score of -5.67, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -5.67 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $18.88M over the last 12 months.
| Revenue | $18.88M |
|---|---|
| Revenue Growth (YoY) | +543.96% |
| Gross Profit | $18.88M |
| Operating Income | -$23.97M |
| Pretax Income | $11.20M |
| Net Income | -$10.10M |
| Reported EPS (TTM) | -$2.39 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 86.90% of the $67.95M in total assets.
| Cash and Equivalents | $8.23M |
|---|---|
| Total Debt | $549.00K |
| Net Cash | $7.68M |
| Net Cash Per Share | $0.65 |
| Working Capital | $43.70M |
| Shareholder Equity | $59.05M |
| Book Value Per Share | $4.99 |
| Total Assets | $67.95M |
| Total Liabilities | $8.90M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$12.05M |
|---|---|
| FCF Per Share | -$1.21 |
| Depreciation and Amortization | $246.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -126.97%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -126.97% |
| Pretax Margin | 59.30% |
| Net Margin | -53.50% |
| Gross Margin (5Y Average) | 97.77% |
Dividends and Yields
SCYX does not pay a dividend.
| Buyback Yield | -109.34% |
|---|---|
| Shareholder Yield | -109.34% |
Stock Splits
The last split was a 1-for-8 reverse split on Jun 1, 2026.
| Last Split Date | Jun 1, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:8 |
Peer Position
Against 7 similar companies, SCYX has the 4th highest P/S and the 4th highest ROIC.
P/S RatioPeer median 1.6x
ROICPeer median -18.14%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -7.46%
| P/S Ratio | 1.8x vs 1.6x median |
|---|---|
| ROIC | -16.41% vs -18.14% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +543.96% vs -7.46% median |
Analyst Forecast
Consensus estimates put revenue growth at -31.43% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -31.43% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About SCYX
What is SCYX's market cap?
Scynexis has a market cap of $31.95M. Its enterprise value, which adds debt and subtracts cash, is $24.27M.
How many shares of SCYX are outstanding?
Scynexis has 11.84M shares outstanding.
Does SCYX pay a dividend?
No. Scynexis does not pay a dividend.
How much debt does SCYX have?
Scynexis has $549.00K of total debt and $8.23M of cash and equivalents, a net cash position of $7.68M.
SCYX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors